Breast Cancer Therapy Using Antibody-Endostatin Fusion Proteins

Abstract

To produce a more effective form of Herceptin and improve efficacy of human endostatin, we have constructed an anti-HER2 IgG3-human endostatin fusion protein by joining human endostatin to the 3 end of humanized anti-HER2 IgG3. The wild type and the mutant type (P125A) of human endostatin were constructed with FLAG tagging to distinguish from the endogenous human endostatin. The anti-HER2 IgG3-huEndo fusion proteins were constructed as wild type and mutant type (P125A) and were stably transfected into B myeloma cells. The secreted huEndo fusion proteins have a molecular weight of 220 kDa for the anti-HER2 IgG3-CH3-huEndo fusion protein and 160 kDa for the anti-HER2 IgG3-Hinge-huEndo fusion protein. The huEndo fusion proteins were faithfully secreted as the fully assembled H2L2 form.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Apr 01, 2006
Accession Number
ADA455083

Entities

People

  • Seung-uon Shin

Organizations

  • University of Miami

Tags

DTIC Thesaurus Topics

  • Antibodies
  • Biomedical Research
  • Blood
  • Blood Vessels
  • Breast Cancer
  • Cells
  • Diseases And Disorders
  • Endothelial Cells
  • Materials
  • Molecular Weight
  • Molecules
  • Neoplasms
  • Patent Applications
  • Patents
  • Schematic Diagrams
  • Therapy
  • United States

Fields of Study

  • Biology

Readers

  • Aerospace Propulsion Engineering.
  • Canadian European Scientific Immigration and Epilepsy Clearance Studies
  • Molecular Biology and Genetics